Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
55.61
-0.43 (-0.77%)
At close: Sep 26, 2025, 4:00 PM EDT
55.79
+0.18 (0.32%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.94
Revenue / Employee
4,032,864 DKK
Employees
77,349
Market Cap
242.68B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Thermo Fisher Scientific | 43.21B |
NVO News
- 1 day ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 1 day ago - Novo Nordisk: Wegovy Sales Soar, Trump Tariffs No Threat - Seeking Alpha
- 2 days ago - DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025 - GlobeNewsWire
- 2 days ago - Denmark's 'Novo Town' holds its breath as Wegovy fever fades - Reuters
- 6 days ago - Here Are 2 Defensive Positions That Are Worth A Look Now - Seeking Alpha
- 6 days ago - Ozempic's Maker Got Crushed. The Rebound Is Under Way. - WSJ
- 8 days ago - Novo Nordisk: Don't Be Deterred By Outlook Downgrades - Seeking Alpha
- 8 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - GlobeNewsWire